コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 e spots, which were classically described as subretinal.
4 in this case demonstrated if the size of the subretinal abscess is smaller than four disc areas, pars
6 of metastatic endophthalmitis combined with subretinal abscess with successful visual outcome after
8 etion protected the mice from the pathogenic subretinal accumulation of mononuclear phagocytes (MP) t
9 icient mice develop age- and stress- related subretinal accumulation of MPs, which is associated with
13 ation of CD47 accelerated resolution of both subretinal and peritoneal inflammation, with implication
14 graphy, 83% had fluid (61% intraretinal, 38% subretinal, and 36% sub-retinal pigment epithelium).
15 erence tomography (presence of intraretinal, subretinal, and subretinal pigment epithelium fluid; thi
17 etinography and microperimetry indicate that subretinal brilliant blue G might cause focal macular da
18 ents with GA and show their association with subretinal CD14(+)mononuclear phagocyte (MP) infiltratio
19 orse than -6.0 diopters with the presence of subretinal/choroidal neovascularization as indicated by
20 c CNV was defined as HM with the presence of subretinal/choroidal neovascularization indicated by the
24 reduced visual acuity and bilateral diffuse, subretinal, confluent, placoid, and multifocal chorioret
25 tudy, we evaluated the epigenetic changes of subretinal delivering NP-cDNA vs. NP-sgRho in the RKO mo
28 he activity of the protective axis of RAS by subretinal delivery of an AAV8 (Y733F)-ACE2 vector would
31 ssed long-term functional outcomes following subretinal delivery of the human melanopsin gene (OPN4)
32 ty studies in the macaques demonstrated that subretinal delivery of UshStat is safe and well-tolerate
34 e pseudodrusen in these eyes correlated with subretinal deposition of material in multiple imaging mo
35 se presented with acquired macular yellowish subretinal deposits on funduscopic examination that corr
37 uorescent on fundus autofluorescence, and as subretinal deposits on spectral-domain optical coherence
40 bility of and clinical response to a single, subretinal dose of human umbilical tissue-derived cells
41 ion, eyes were assigned to receive a single, subretinal dose of palucorcel (ranging from 6.0 x 10(4)
42 D, which is characterized by accumulation of subretinal drusen deposits and complement-driven inflamm
44 l vascular features of eyes with and without subretinal drusenoid deposits (SDD), using swept-source
45 ility to detect reticular pseudodrusen (RPD)/subretinal drusenoid deposits (SDDs) using 12x12-mm wide
46 re was the likelihood of association between subretinal drusenoid deposits and large choroidal vessel
47 nstrate that there is no concordance between subretinal drusenoid deposits and large choroidal vessel
48 ctivity was qualitatively reduced by stage 1 subretinal drusenoid deposits and was greatly reduced by
49 s a consequence, hypotheses postulating that subretinal drusenoid deposits are associated with large
52 proportion of geometric probes intersecting subretinal drusenoid deposits to be 0.28, large choroida
57 T1 in humans may underlie the development of subretinal drusenoid deposits, a hallmark of age-related
58 followed by choroid thickness in absence of subretinal drusenoid deposits, photoreceptor outer segme
62 features included subretinal fluid (n = 6), subretinal exudation (n = 6), epiretinal membrane (n = 3
64 T-cells was reduced in nAMD patients without subretinal fibrosis (P = 0.026) compared to patients wit
66 potential therapeutic target for preventing subretinal fibrosis development in neovascular age-relat
70 es in the biweekly induction group developed subretinal fibrosis vs no eyes in the other 2 groups (P
76 r with a Type 3 regression pattern, pre- and subretinal fibrovascular tissue consistent with PVR, and
77 ess on B-scan ultrasonography (63% vs. 84%), subretinal fluid (58% vs. 90%), and orange pigment (50%
79 , 2.4; CI, 1.7-3.6) versus </=75 mum, foveal subretinal fluid (aHR, 1.5; CI, 1.1-2.0) versus no subre
80 orrhage (n = 2), retinal hemorrhage (n = 4), subretinal fluid (n = 4), and/or intraretinal exudation
82 pigment epithelial alterations (n = 9; 53%), subretinal fluid (n = 5; 29%), and orange pigment (n = 3
86 y (BCVA) at baseline (P = .001), presence of subretinal fluid (P = .001), and retinal angiomatous pro
88 = 0.005), -0.200 (-1.20, 0.60) in cases with subretinal fluid (p = 0.207), 0.000 (-0.60, 0.30) in pig
89 ween the tumor and the optic disc (P=0.026), subretinal fluid (P=0.035), thickness of residual tumor
91 orrected visual acuity (BCVA), resolution of subretinal fluid (SRF) demonstrated by optical coherence
95 resence of intraretinal cystoid fluid (IRC), subretinal fluid (SRF), and pigment epithelial detachmen
96 ed OCT, including intraretinal cysts (IRCs), subretinal fluid (SRF), and pigment epithelial detachmen
97 changes, such as intraretinal cysts (IRCs), subretinal fluid (SRF), and pigment epithelial detachmen
98 ns for presence of intraretinal fluid (IRF), subretinal fluid (SRF), and sub-retinal pigment epitheli
99 wth of RPE/drusenoid material and persistent subretinal fluid (SRF), but also a RPE-independent visua
100 s included intraretinal cystoid fluid (IRC), subretinal fluid (SRF), pigment epithelial detachment, a
103 a vitrectomy alone with complete drainage of subretinal fluid achieves a high reattachment rate in th
105 njection due to the presence of intraretinal/subretinal fluid and pigment epithelial detachment (PED)
107 solved after delivery with regression of the subretinal fluid and the disappearance of subfoveal exud
108 ness (CMT), and the presence of intraretinal/subretinal fluid and the height and presence of PED were
109 raster scans were evaluated for intraretinal/subretinal fluid and, when applicable, vitreomacular tra
111 In 11 of 19 patients with intraretinal or subretinal fluid at baseline judged to be reversible, si
113 a shallow decline in acuity with increasing subretinal fluid but a much steeper decline with equival
114 s causes of retinal fluid, but was worst for subretinal fluid compared to intraretinal or sub-retinal
115 b-treated eyes had resolved intraretinal and subretinal fluid compared with aflibercept-treated eyes.
123 ol may reduce central subfield thickness and subretinal fluid in eyes with persistent exudation despi
125 asing subretinal hyperreflective material or subretinal fluid in this circumstance reduces vision fur
126 rs (68.5% vs. 55.3%; P = 0.003), and to have subretinal fluid on OCT (86.7% vs. 81.0%; P = 0.047).
128 al foveal thickness (CFT), and resolution of subretinal fluid on optical coherence tomography at 1 an
130 reatment criteria relying on intraretinal or subretinal fluid or new hemorrhages may be expanded to i
136 acteristics and variations in a patient with subretinal fluid secondary to a carotid cavernous fistul
137 of the left eye showed a geographic patch of subretinal fluid temporal to the macula that was associa
138 .49; 95% CI, 0.29-0.82), OCT measurements of subretinal fluid thickness of >25 mu (aHR, 0.52; 95% CI,
141 successfully re-attached surgically and the subretinal fluid was gradually absorbed within three mon
143 revealed a thicker choroidal thickness when subretinal fluid was present as compared to that observe
145 er subretinal tissue complex and presence of subretinal fluid were associated with less GA developmen
146 t or multiple recurrences of intraretinal or subretinal fluid while receiving monthly bevacizumab or
149 ad well-circumscribed vessels, 86% (6/7) had subretinal fluid, and 14% (1/7) had intraretinal fluid.
151 cysts, epiretinal membranes, microaneurysms, subretinal fluid, and outer layer disruption/reflectivit
152 with gradual resolution of intraretinal- and subretinal fluid, and remained stable in 12 months.
153 ponse depended on baseline BCVA, presence of subretinal fluid, and retinal angiomatous proliferation,
154 scan for the presence of intraretinal fluid, subretinal fluid, and sub-retinal pigment epithelium flu
155 inal fluid (aHR, 1.5; CI, 1.1-2.0) versus no subretinal fluid, and subretinal hyperreflective materia
156 hickness at the foveal center of the retina, subretinal fluid, and subretinal tissue complex), visual
157 3 %) pigment epithelial detachment, 6 (55 %) subretinal fluid, in 29 (39 %) eyes regardless of the le
158 depigmentation area, subretinal haemorrhage, subretinal fluid, macula thickness, macular scar, subret
159 e impact on acuity of defined OCT changes in subretinal fluid, subretinal hyperreflective material, a
160 T), as well as associated features including subretinal fluid, were recorded before PDT and during fo
161 underwent PPV alone and complete drainage of subretinal fluid, with air, 20% sulfur hexafluoride (SF6
171 ated with signs of active myopic CNV (either subretinal fluid/intraretinal cysts on SD OCT or dye lea
172 nts aged 23 to 71 years underwent unilateral subretinal gene therapy for genetically confirmed choroi
173 ate that the optimal intervention window for subretinal gene therapy is within the first 2 to 3 decad
174 e-related adverse events (subconjunctival or subretinal haemorrhage and mild cell debris in the anter
175 fects/pigment mottling, depigmentation area, subretinal haemorrhage, subretinal fluid, macula thickne
178 aphs for the presence and size of retinal or subretinal hemorrhage at baseline and years 1 and 2.
179 able photographs, 724 (62.1%) had retinal or subretinal hemorrhage at baseline; 84.4% of hemorrhages
180 of 1078 participants (4.08%) had retinal or subretinal hemorrhage detected on 1- or 2-year photograp
181 nal fluid resolved in 13/18 eyes (72 %), and subretinal hemorrhage resolved in 6/8 eyes (75 %) respec
182 ) retinal pigment epithelium (RPE) tear, (3) subretinal hemorrhage, (4) foveal scar tissue of recent
183 ncluded stabilization of vision, presence of subretinal hemorrhage, serous detachment, retinal pigmen
189 ighly myopic patients with CNV and showing a subretinal hyperreflective exudation on SD OCT were incl
190 mean number of injections 1.8 +/- 0.6), the subretinal hyperreflective exudation regressed completel
192 re and after anti-VEGF therapy, based on the subretinal hyperreflective exudation thickness, retinal
195 traretinal fluid (82.5% vs 51.0%, P < .001), subretinal hyperreflective material (84.5% vs 44.2%, P <
197 CI, 1.1-2.0) versus no subretinal fluid, and subretinal hyperreflective material (SHRM) (aHR, 1.7; CI
200 sions on fundus autofluorescence imaging and subretinal hyperreflective material on spectral-domain o
203 of defined OCT changes in subretinal fluid, subretinal hyperreflective material, and loss of externa
205 -1beta receptor preserved choroid, decreased subretinal hypoxia, and prevented RPE/photoreceptor deat
210 retina coculture system and in light-induced subretinal inflammation of Cx3cr1-deficient mice in vivo
214 lacking heparin binding transduce retina by subretinal injection and display a remarkable ability to
216 n a phase 1 clinical trial received a second subretinal injection in their contralateral eye in a fol
219 dose-escalation study involving a unilateral subretinal injection of a recombinant adeno-associated v
229 , long-term results in patients treated with subretinal injections for Leber congenital amaurosis hav
231 133 scans), 7 25-line raster scans confirmed subretinal/intraretinal fluid not identified by the 6-li
234 With SD OCT imaging, the cloudy vitelliform subretinal lesions appeared as hyperreflective debris ab
235 findings suggest that gray hyper-reflective subretinal lesions might be considered as a qualitative
237 cular edema (CME), intraretinal exudates and subretinal lipid aggregation, dry or edematous radial fo
238 lopathy appeared with hazy indistinct yellow subretinal material resembling the vitelliform lesions f
239 helium and ellipsoids zones, with or without subretinal material suggestive of subretinal fibrosis.
240 rate of increase in pure atrophic areas (no subretinal material) was 0.7 +/- 0.8 mm(2) per year, wit
242 We previously demonstrated that pathogenic subretinal mononuclear phagocytes (MPs) accumulate in Cx
243 otected Cx3cr1(GFP/GFP) mice against harmful subretinal MP accumulation observed in Cx3cr1(GFP/GFP)TR
246 of APOE, interleukin-6, and CCL2 and develop subretinal MP accumulation, photoreceptor degeneration,
248 ficient (Vldlr (-/-) ) mice with spontaneous subretinal neovascularization, whereas a RORalpha agonis
251 s currently in human clinical trials rely on subretinal or intravitreal injections of adeno-associate
252 corticosteroid exposure, or fluid location (subretinal or pigment epithelial detachment; all P > 0.0
253 n, and in 2 patients flow was limited to the subretinal or sub-retinal pigment epithelial space.
254 y (presence of intraretinal, subretinal, and subretinal pigment epithelium fluid; thickness at the fo
256 2%) of 18 patients had patches of increasing subretinal pigmentation consistent with transplanted ret
257 ture development of a neurotransmitter-based subretinal prosthesis offering more naturalistic vision
258 a suggest that melanopsin gene therapy via a subretinal route may be a viable and stable therapeutic
259 (6%), a choroidal neovascularization-related subretinal scar in 3 (19%), and loss of ellipsoid zone a
261 The solid intraretinal retinoblastoma and subretinal seeds showed regression in all eyes following
264 etinal circulation but involved not only the subretinal space but also could infiltrate the remaining
265 y transduce the retina when delivered to the subretinal space but show limited success when delivered
267 the homeostatic elimination of MPs from the subretinal space mediated by thrombospsondin-1 (TSP-1) a
270 s membrane, loss of photoreceptors, cells in subretinal space, and a reduction of choroidal vessels.
271 proteins, atrophic cell extrusions into the subretinal space, and compensatory proliferation of peri
273 ion with appearance of Iba-1(+) cells in the subretinal space, severe photoreceptor cell death, and i
278 he proliferation of vessels in the outer and subretinal spaces may be in part compensatory for poor r
279 Invasion by new vessels into the outer and subretinal spaces occurred subjacent to the regions show
280 deeper vascular invasion into the outer and subretinal spaces were optically dissected in en face im
283 rs3750846 SNP at the ARMS2/HTRA1 locus with subretinal/sub-retinal pigment epithelial (RPE) hemorrha
284 ion of the SNP at the ARMS2/HTRA1 locus with subretinal/sub-RPE hemorrhage and poorer visual acuity a
286 6), SRF (ICC = 0.88; 95% CI, 0.86-0.89), and subretinal tissue complex (ICC = 0.91; 95% CI, 0.89-0.92
288 rmally thin retina, greater thickness of the subretinal tissue complex on OCT, and subfoveal geograph
289 R, 2.4; CI, 1.7-3.6) versus <120 mum, foveal subretinal tissue complex thickness >275 mum (aHR, 2.4;
290 -retinal pigment epithelium (RPE) fluid, and subretinal tissue complex thickness decreased in all tre
291 ss of >25 mu (aHR, 0.52; 95% CI, 0.35-0.78), subretinal tissue complex thickness of >275 compared wit
292 med manual measurements of retinal, SRF, and subretinal tissue complex thicknesses at the foveal cent
296 primary endpoints safety and tolerability of subretinal transplantation of hESC-derived retinal pigme
297 g photoreceptor replacement strategies using subretinal transplantation of photoreceptor precursor ce
299 1 (sub-retinal pigment epithelium), type 2 (subretinal), type 3 (intraretinal), and mixed neovascula
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。